These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7783880)

  • 41. Long-term MPTP-treated monkeys are resistant to GM1 systemic therapy.
    Emborg ME; Colombo JA
    Mol Chem Neuropathol; 1994 Jan; 21(1):75-82. PubMed ID: 8179773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug.
    Argentino C; Sacchetti ML; Toni D; Savoini G; D'Arcangelo E; Erminio F; Federico F; Milone FF; Gallai V; Gambi D
    Stroke; 1989 Sep; 20(9):1143-9. PubMed ID: 2672425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GM1 ganglioside treatment of spontaneously hypertensive stroke prone rats.
    Hernandez NE; MacDonall JS; Stier CT; Belmonte A; Fernandez R; Karpiak SE
    Exp Neurol; 1994 Mar; 126(1):95-100. PubMed ID: 8157130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study.
    Altman RD; Lang AE; Postuma RB
    Mov Disord; 2011 Nov; 26(13):2427-31. PubMed ID: 21953603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
    Hauser RA; Cantillon M; Pourcher E; Micheli F; Mok V; Onofrj M; Huyck S; Wolski K
    Lancet Neurol; 2011 Mar; 10(3):221-9. PubMed ID: 21315654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
    Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
    Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.
    Pestronk A; Choksi R
    Neurology; 1997 Nov; 49(5):1289-92. PubMed ID: 9371910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
    Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis.
    Pestronk A; Adams RN; Clawson L; Cornblath D; Kuncl RW; Griffin D; Drachman DB
    Neurology; 1988 Sep; 38(9):1457-61. PubMed ID: 3412595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monosialoganglioside GM1 in cerebral ischemia.
    Carolei A; Fieschi C; Bruno R; Toffano G
    Cerebrovasc Brain Metab Rev; 1991; 3(2):134-57. PubMed ID: 1854596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trial of ganglioside GM1 in acute stroke.
    Hoffbrand BI; Bingley PJ; Oppenheimer SM; Sheldon CD
    J Neurol Neurosurg Psychiatry; 1988 Sep; 51(9):1213-4. PubMed ID: 3066849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.
    Villafane G; Thiriez C; Audureau E; Straczek C; Kerschen P; Cormier-Dequaire F; Van Der Gucht A; Gurruchaga JM; Quéré-Carne M; Evangelista E; Paul M; Defer G; Damier P; Remy P; Itti E; Fénelon G
    Eur J Neurol; 2018 Jan; 25(1):120-127. PubMed ID: 28960663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced Autophagy Contributes to Protective Effects of GM1 Ganglioside Against Aβ1-42-Induced Neurotoxicity and Cognitive Deficits.
    Dai R; Zhang S; Duan W; Wei R; Chen H; Cai W; Yang L; Wang Q
    Neurochem Res; 2017 Aug; 42(8):2417-2426. PubMed ID: 28497346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.